Literature DB >> 17311284

Metabolic and cardiovascular risk factors in subjects with impaired fasting glucose: the 100 versus 110 mg/dL threshold.

Francesco Andreozzi1, Elena Succurro, Maria Rosaria Mancuso, Maria Perticone, Angela Sciacqua, Francesco Perticone, Giorgio Sesti.   

Abstract

BACKGROUND: In 2003, the American Diabetes Association (ADA) established a new cutoff for impaired fasting glucose (IFG) by reducing it from 110 to 100 mg/dL. This change was challenged as to its appropriateness. A few studies have examined the impact of the ADA(2003) threshold of IFG on metabolic and cardiovascular risk factors.
METHODS: We examined whether metabolic and cardiovascular risk factors, including inflammatory biomarkers, differ in subjects with the new ADA(2003) threshold of IFG (IGF100) as compared with subjects with the old ADA(1997) threshold of IFG (IFG110) in a cohort of 946 nondiabetic Italian Caucasians (fasting plasma glucose < 126 mg/dL).
RESULTS: As compared with normal fasting glucose (NFG), subjects with IFG100 and IFG110 had higher body mass index (BMI), waist circumference, total and low density lipoprotein (LDL) cholesterol, triglyceride, fasting and 2-h post-challenge plasma glucose, fasting insulin, systolic blood pressure, and lower levels of high density lipoprotein (HDL) and insulin-like growth factor I (IGF-I). In a logistic regression analysis with adjustment for age and gender, IFG110 was associated with higher risk of post-challenge glucose intolerance as compared with IFG100. As compared with IFG100, subjects with IFG110 have significantly lower levels of circulating IGF-I. As compared with NFG, IFG110, but not IFG100, showed a significant association with increased levels of inflammatory markers including white blood cell count (WBCC), and C-reactive protein (CRP). Both CRP and WBCC were correlated with 2-h plasma glucose but not with fasting plasma glucose (FPG).
CONCLUSIONS: The data show that IFG110 is associated with a worse metabolic and cardiovascular risk profile as compared with IFG100. (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17311284     DOI: 10.1002/dmrr.724

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  11 in total

Review 1.  Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.

Authors:  Stanley M H Chan; Stavros Selemidis; Steven Bozinovski; Ross Vlahos
Journal:  Pharmacol Ther       Date:  2019-02-26       Impact factor: 12.310

2.  The route to diabetes: Loss of complexity in the glycemic profile from health through the metabolic syndrome to type 2 diabetes.

Authors:  Juan Churruca; Luis Vigil; Esther Luna; Julian Ruiz-Galiana; Manuel Varela
Journal:  Diabetes Metab Syndr Obes       Date:  2008-08-11       Impact factor: 3.168

Review 3.  Prevalence of Pre-Diabetes across Ethnicities: A Review of Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) for Classification of Dysglycaemia.

Authors:  Wilson C Y Yip; Ivana R Sequeira; Lindsay D Plank; Sally D Poppitt
Journal:  Nutrients       Date:  2017-11-22       Impact factor: 5.717

4.  Association between Serum Mg2+ Concentrations and Cardiovascular Organ Damage in a Cohort of Adult Subjects.

Authors:  Elettra Mancuso; Maria Perticone; Rosangela Spiga; Carolina Averta; Mariangela Rubino; Teresa Vanessa Fiorentino; Sofia Miceli; Gaia Chiara Mannino; Angela Sciacqua; Elena Succurro; Francesco Perticone; Giorgio Sesti; Francesco Andreozzi
Journal:  Nutrients       Date:  2020-04-29       Impact factor: 5.717

Review 5.  The Clinical Significance and Potential Role of C-Reactive Protein in Chronic Inflammatory and Neurodegenerative Diseases.

Authors:  Ying-Yi Luan; Yong-Ming Yao
Journal:  Front Immunol       Date:  2018-06-07       Impact factor: 7.561

6.  Are Circulating Mg2+ Levels Associated with Glucose Tolerance Profiles and Incident Type 2 Diabetes?

Authors:  Rosangela Spiga; Gaia Chiara Mannino; Elettra Mancuso; Carolina Averta; Claudia Paone; Mariangela Rubino; Angela Sciacqua; Elena Succurro; Francesco Perticone; Francesco Andreozzi; Giorgio Sesti
Journal:  Nutrients       Date:  2019-10-14       Impact factor: 5.717

7.  Fasting glucose level and the risk of incident atherosclerotic cardiovascular diseases.

Authors:  Chanshin Park; Eliseo Guallar; John A Linton; Duk-Chul Lee; Yangsoo Jang; Dong Koog Son; Eun-Jeong Han; Soo Jin Baek; Young Duk Yun; Sun Ha Jee; Jonathan M Samet
Journal:  Diabetes Care       Date:  2013-02-12       Impact factor: 19.112

8.  Asymmetric dimethylarginine plasma levels and endothelial function in newly diagnosed type 2 diabetic patients.

Authors:  Angela Sciacqua; Nadia Grillo; Michele Quero; Giorgio Sesti; Francesco Perticone
Journal:  Int J Mol Sci       Date:  2012-10-24       Impact factor: 5.923

9.  Comparison of the Effects of Fasting Glucose, Hemoglobin A1c, and Triglyceride-Glucose Index on Cardiovascular Events in Type 2 Diabetes Mellitus.

Authors:  Wei-Yu Su; Szu-Chia Chen; Yu-Ting Huang; Jiun-Chi Huang; Pei-Yu Wu; Wei-Hao Hsu; Mei-Yueh Lee
Journal:  Nutrients       Date:  2019-11-19       Impact factor: 5.717

10.  The Functional Polymorphism of DDAH2 rs9267551 Is an Independent Determinant of Arterial Stiffness.

Authors:  Carolina Averta; Elettra Mancuso; Rosangela Spiga; Sofia Miceli; Elena Succurro; Teresa Vanessa Fiorentino; Maria Perticone; Gaia Chiara Mannino; Prapaporn Jungtrakoon Thamtarana; Angela Sciacqua; Giorgio Sesti; Francesco Andreozzi
Journal:  Front Cardiovasc Med       Date:  2022-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.